141 related articles for article (PubMed ID: 34643804)
21. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma.
Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ
Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612
[TBL] [Abstract][Full Text] [Related]
22. The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis.
Ghouzlani A; Lakhdar A; Rafii S; Karkouri M; Badou A
Sci Rep; 2021 Nov; 11(1):21504. PubMed ID: 34728682
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients.
Janke F; Angeles AK; Riediger AL; Bauer S; Reck M; Stenzinger A; Schneider MA; Muley T; Thomas M; Christopoulos P; Sültmann H
Clin Epigenetics; 2022 Dec; 14(1):163. PubMed ID: 36461127
[TBL] [Abstract][Full Text] [Related]
24. Study on the Prognostic Values of Dynactin Genes in Low-Grade Glioma.
Su X; Li H; Chen S; Qin C
Technol Cancer Res Treat; 2021; 20():15330338211010143. PubMed ID: 33896271
[TBL] [Abstract][Full Text] [Related]
25. Proteomics reveals protein phosphatase 1γ as a biomarker associated with Hippo signal pathway in glioma.
Xue J; Sang W; Su LP; Gao HX; Cui WL; Abulajiang G; Wang Q; Zhang J; Zhang W
Pathol Res Pract; 2020 Nov; 216(11):153187. PubMed ID: 32919304
[TBL] [Abstract][Full Text] [Related]
26. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
27. Integrative analysis of TP73 profile prognostic significance in WHO grade II/III glioma.
Chen Y; Wang Y; He Q; Wang W; Zhang T; Wang Z; Dong J; Lan Q; Zhao J
Cancer Med; 2021 Jul; 10(13):4644-4657. PubMed ID: 34121368
[TBL] [Abstract][Full Text] [Related]
28. CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma.
Sibin MK; Bhat DI; Narasingarao KV; Lavanya Ch; Chetan GK
Tumour Biol; 2015 Sep; 36(10):7607-14. PubMed ID: 25921285
[TBL] [Abstract][Full Text] [Related]
29. In silico identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma.
Lvu W; Fei X; Chen C; Zhang B
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32725165
[TBL] [Abstract][Full Text] [Related]
30. DDX3X Biomarker Correlates with Poor Survival in Human Gliomas.
Hueng DY; Tsai WC; Chiou HY; Feng SW; Lin C; Li YF; Huang LC; Lin MH
Int J Mol Sci; 2015 Jul; 16(7):15578-91. PubMed ID: 26184164
[TBL] [Abstract][Full Text] [Related]
31. Significance of tumor protein p53 mutation in cellular process and drug selection in brain lower grade (WHO grades II and III) glioma.
Guo CF; Zhuang Y; Chen Y; Chen S; Peng H; Zhou S
Biomark Med; 2020 Aug; 14(12):1139-1150. PubMed ID: 32664789
[No Abstract] [Full Text] [Related]
32. Correlation of diffusion tensor, dynamic susceptibility contrast MRI and (99m)Tc-Tetrofosmin brain SPECT with tumour grade and Ki-67 immunohistochemistry in glioma.
Alexiou GA; Zikou A; Tsiouris S; Goussia A; Kosta P; Papadopoulos A; Voulgaris S; Kyritsis AP; Fotopoulos AD; Argyropoulou MI
Clin Neurol Neurosurg; 2014 Jan; 116():41-5. PubMed ID: 24309151
[TBL] [Abstract][Full Text] [Related]
33. Dynamics of circulating hypoxia-mediated miRNAs and tumor response in patients with high-grade glioma treated with bevacizumab.
Siegal T; Charbit H; Paldor I; Zelikovitch B; Canello T; Benis A; Wong ML; Morokoff AP; Kaye AH; Lavon I
J Neurosurg; 2016 Oct; 125(4):1008-1015. PubMed ID: 26799295
[TBL] [Abstract][Full Text] [Related]
34. ACTC1 as an invasion and prognosis marker in glioma.
Ohtaki S; Wanibuchi M; Kataoka-Sasaki Y; Sasaki M; Oka S; Noshiro S; Akiyama Y; Mikami T; Mikuni N; Kocsis JD; Honmou O
J Neurosurg; 2017 Feb; 126(2):467-475. PubMed ID: 27081897
[TBL] [Abstract][Full Text] [Related]
35. HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma.
Zhang JX; Han L; Bao ZS; Wang YY; Chen LY; Yan W; Yu SZ; Pu PY; Liu N; You YP; Jiang T; Kang CS;
Neuro Oncol; 2013 Dec; 15(12):1595-603. PubMed ID: 24203894
[TBL] [Abstract][Full Text] [Related]
36. Systemic inflammatory biomarkers in primary central nervous system lymphoma versus high-grade glioma: exploratory, comparative and correlative analysis.
Gupta T; Nayak P; Baviskar Y; Gupta M; Moiyadi A; Epari S; Janu A; Purandare N; Rangarajan V; Bagal B; Chatterjee A; Sastri GJ
CNS Oncol; 2022 Jun; 11(2):CNS83. PubMed ID: 35373582
[TBL] [Abstract][Full Text] [Related]
37. Comparison of
Unterrainer M; Fleischmann DF; Diekmann C; Vomacka L; Lindner S; Vettermann F; Brendel M; Wenter V; Ertl-Wagner B; Herms J; Wetzel C; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):580-590. PubMed ID: 30244386
[TBL] [Abstract][Full Text] [Related]
38.
Ge X; Xu M; Cheng T; Hu N; Sun P; Lu B; Wang Z; Li J
Front Immunol; 2022; 13():974346. PubMed ID: 36275718
[TBL] [Abstract][Full Text] [Related]
39. Construction and comprehensive analysis of a competitive endogenous RNA network to reveal potential biomarkers for the malignant differentiation of glioma.
Li X; Zhang J; Zhang M; Qi X; Wang S; Teng J
Medicine (Baltimore); 2021 Oct; 100(39):e27248. PubMed ID: 34596120
[TBL] [Abstract][Full Text] [Related]
40. The emerging clinical potential of circulating extracellular vesicles for non-invasive glioma diagnosis and disease monitoring.
Hallal S; Ebrahimkhani S; Shivalingam B; Graeber MB; Kaufman KL; Buckland ME
Brain Tumor Pathol; 2019 Apr; 36(2):29-39. PubMed ID: 30859343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
